Yael Dishon Benattar

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial

Mical Paul, George L. Daikos, Emanuele Durante‐Mangoni et al. · The Lancet Infectious Diseases · 2018 · 593 citations

Severe Infections, Health Sciences, Antibiotics +9

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial

Yaakov Dickstein, Jonathan Lellouche, Maayan Ben Dalak Amar et al. · Clinical Infectious Diseases · 2018 · 119 citations

Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes

Amir Nutman, Jonathan Lellouche, Elizabeth Temkin et al. · Clinical Microbiology and Infection · 2020 · 75 citations

Antimicrobial Susceptibility, Health Sciences, Antibiotics +11

The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study

Yael Dishon Benattar, Muna Omar, Oren Zusman et al. · Clinical Infectious Diseases · 2016 · 53 citations · Full text

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol

Yaakov Dickstein, Leonard Leibovici, Dafna Yahav et al. · BMJ Open · 2016 · 45 citations · Full text